Company: RGNT
Filing Date: 2025-01-24
Form Type: DRS
Source: 0001213900-25-006245
Chunk: 285

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-24
Form: DRS
Chunk 285
---
91 | ) |
| Temporary deductible difference                                                                                  |     |                         |   (26 | ) |     |   |   (94 | ) |
| Losses for which a valuation allowance was provided or benefit from loss carryforwards and permanent differences |     |                         |  (460 | ) |     |   |  (148 | ) |
| Income tax expense                                                                                               |     | $                       |     - |   |     | $ |     - |   |

<div align='center'>F-36</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 9:- | COMMITMENTS AND CONTINGENCIES |

| 1. | Between September 2004 and December 2015, the Company received funding                                                                  
 from the IIA for its participation in certain research and development activities, based on budgets approved by the IIA, subject to the 
 fulfillment of specified milestones. The Company is committed to pay royalties to the IIA on proceeds from sale of products related to  
 research and development activities of which the IIA participates by way of grants. According to the funding terms, royalties between   
 3% and 4.5% are payable on sales of developed products funded, up to 100% of the grant received by the Company, linked to U.S. dollar   
 and bearing Term SOFR interest rate. In the case of failure of a funded research and development activity, the Company is not obligated 
 to pay any such royalties to the IIA. As of December 31, 2023, total contingent obligation to IIA is at the amount of $2,635 (including 
 interest at the amount of $291).                                                                                                        |

| 2. | In February 2018, the Company entered into a services agreement with Baxter Healthcare Corporation (the “Baxter Services Agreement” and “Baxter”, respectively), pursuant to which the Company agreed to purchase certain services from the third party in connection with GelrinC. In April 2022, we amended the Baxter Services Agreement to replace Teva Medical (Marketing) Ltd. (“Teva”) as the supplier of Tisseel under the Supply Agreement for GelrinC with Baxter as Teva ceased to distribute Tisseel in the territory of Israel. |

Under the Baxter Services Agreement, Baxter
provides the Company with quality, regulatory and technical support, for up to a maximum aggregate of 40 man